Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1

OBJECTIVES: To present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study. METHODS: This post hoc analysis reports data from Taiwanese patients originally randomized to subcutaneous secukinumab 150 or 75mg or placebo every...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Jui-Cheng, Wei, James Cheng-Chung, Deodhar, Atul, Martin, Ruvie, Porter, Brian, McCreddin, Suzanne, Talloczy, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725874/
https://www.ncbi.nlm.nih.gov/pubmed/33324394
http://dx.doi.org/10.3389/fimmu.2020.561748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725874/
https://www.ncbi.nlm.nih.gov/pubmed/33324394
http://dx.doi.org/10.3389/fimmu.2020.561748

Ejemplares similares